| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
PVLA
Palvella Therapeutics
|
May 21, 2026 | BUY |
Strong Buy
+46.0% avg upside
27 analysts
|
$210.00
86.44% Upside
|
-2.4% |
|
DNTH
Dianthus Therapeutics
|
May 11, 2026 | HOLD |
Strong Buy
+9.8% avg upside
29 analysts
|
— | -9.5% |
|
BBIO
BridgeBio Pharma
|
May 11, 2026 | HOLD |
Strong Buy
+36.6% avg upside
34 analysts
|
— | +4.2% |
|
TBPH
Theravance Biopharma
|
Mar 05, 2026 | HOLD |
Buy
+11.6% avg upside
18 analysts
|
$13.67
18.11% Downside
|
+20.0% |
|
INVA
Innoviva
|
Feb 26, 2026 | BUY |
Buy
+26.8% avg upside
12 analysts
|
$35.00
54.65% Upside
|
-3.8% |
|
LGND
Ligand Pharma
|
Nov 07, 2025 | BUY |
Strong Buy
-18.2% avg upside
15 analysts
|
$275.00
4.54% Upside
|
+30.0% |
|
MBX
MBX Biosciences, Inc.
|
Nov 07, 2025 | BUY |
Strong Buy
+58.6% avg upside
14 analysts
|
$80.00
92.32% Upside
|
+56.8% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.